(Q36796538)

English

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women

scientific article published on 13 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Philippe Mayaud

12

object named as

Philippe Mayaud

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Richard J. Hayes

object named as

Richard Hayes

13

0 references

object named as

Saidi Kapiga

11

0 references

John Changalucha

4

object named as

John Changalucha

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Deborah Watson-Jones

2

object named as

Deborah Watson-Jones

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

3

object named as

Nancy Kiviat

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Papa Salif Sow

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Khardiata Diallo Mbaye

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Joelle Brown

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Kouro Bousso

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Bazil Kavishe

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Aura Andreasen

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Macoumba Toure

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Marie Lebacq

14

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Marjan Herazeh

15

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Florence Thomas

16

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Dominique Descamps

17

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

13 December 2012

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

207

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1753-1763

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

randomized experiment

0 references

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Worldwide burden of cervical cancer in 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Chapter 8: Screening for cervical cancer in developing countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Human papillomaviruses in the pathogenesis of anogenital cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

29 September 2017

Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

5 September 2018

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

5 September 2018

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

5 September 2018

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

5 September 2018

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

5 September 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636781

5 September 2018

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/23242542

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/INFDIS/JIS619

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36796538&oldid=1615391104"